San Francisco, California - [August 1, 2024] - Effective treatment options to reduce mortality and prevent long-term morbidity caused by traumatic brain injury (TBI) are lacking in both military and civilian medicine. Over 30 clinical trials for TBI have failed, due in part to inadequate…
Abbott's i-STAT TBI cartridge has received clearance from the U.S. Food and Drug Administration (FDA) to be used with whole blood, allowing doctors to help assess patients with suspected concussion at the patient's bedside and obtain lab-quality results in 15 minutes.
BARDA is partnering with Abbott to broaden the company’s current traumatic brain injury (TBI) test that will aid healthcare providers in diagnosing and determining severity of TBI in adults and children.
Blood tests taken within 24 hours of a traumatic brain injury (TBI) flag which patients are likely to die and which patients are likely to survive with severe disability, according to a study headed by UC San Francisco, the University…
Traumatic Brain Injury: A Roadmap for Accelerating Progress, a new consensus study report from the National Academies of Sciences, Engineering, and Medicine’s Committee on Accelerating Progress in Traumatic Brain Injury Research and Care, examines how progress can be advanced in TBI care and…
New Rochelle, NY, September 16, 2020—Intracranial abnormalities on CT scan in patients with traumatic brain injury (TBI) can be predicted by glial fibrillary acidic protein (GFAP) levels in the blood. These interim findings from the TRACK-TBI study are published in the peer-reviewed…
We are pleased to announce the launch of TRACK-TBI Longitudinal (TRACK-TBI LONG) in May 2019, funded through a competitive grant from the National Football League Scientific Advisory Board. TRACK-TBI LONG will further advance our understanding of TBI’s natural history by extending follow-up of the…
